Dermatomyositis - Epidemiology Forecast - 2034

Dermatomyositis - Epidemiology Forecast - 2034

Key Highlights

Dermatomyositis is a rare inflammatory condition characterized by muscle weakness and distinctive skin rashes. It primarily affects adults and children, leading to significant physical disability if left untreated.

According to DelveInsight’s estimates, in 2023, there were nearly 72 thousand total diagnosed prevalent cases of dermatomyositis in the 7MM, of which nearly 9% were juvenile and 91% were adult.

In the US, the highest cases were found in the 40–59 age group, followed by the 60–79, 18–39, and 0–17 age groups, while the least cases were for the =80 age group, with nearly 14,644, 13,102, 5,395, 4,239, and 1,156 respectively in 2023. The cases are expected to increase during the study period.

As per DelveInsight’s estimates, Japan accounted for nearly 17% of the Total Diagnosed Prevalent Cases of Dermatomyositis in the 7MM in 2023.

In Japan, comorbidities-specific cases, including ILD, CVD, cancer malignancy, and others (osteoporosis, dysphagia, Raynaud’s syndrome, calcinosis, etc.) accounted for 2,455, 2,200, 509, and 7,248 diagnosed prevalent cases, respectively, in 2023. These cases are expected to change during the study period.

DelveInsight’s “Dermatomyositis – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Dermatomyositis, historical and forecasted epidemiology of Dermatomyositis in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034

Dermatomyositis Disease Understanding

Dermatomyositis Overview

Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of connective tissue disorders characterized by progressive muscle weakness. IIM is the umbrella term that includes dermatomyositis, polymyositis (PM), overlap myositis (OM), sporadic inclusion body myositis (IBM), and necrotizing autoimmune myopathy (NAM), also known as immune-mediated necrotizing myopathy (IMNM).

Dermatomyositis is a rare autoimmune disorder characterized by muscle inflammation (myositis) and skin inflammation (dermatitis). Proximal muscle weakness is a hallmark feature, affecting muscles close to the trunk, such as those in the thighs and upper arms, including heliotrope rash (purplish discoloration around the eyes), Gottron’s papules (reddish bumps on knuckles), and photosensitive rash on sun-exposed areas.

The onset of the disease is usually insidious or acute, with a waxing and a waning course. Other findings present in dermatomyositis include Raynaud’s phenomenon, gastrointestinal ulcers, and cardiac symptoms. Systemic symptoms such as fever, malaise, and weight loss are also present,

Dermatomyositis is a complex and heterogeneous condition that occurs in both adults and even in children, juvenile dermatomyositis (JDM). They share the hallmark features of pathognomic skin rash and muscle inflammation but are heterogeneous disorders with various additional features and complications.

Dermatomyositis Diagnosis

The diagnosis involves a combination of clinical evaluation, detection of characteristic physical findings, certain laboratory tests, and imaging studies. Key diagnostic criteria include muscle weakness, characteristic skin rash, elevated muscle enzymes, myositis-associated enzyme levels, electromyography, and muscle biopsy. Muscle biopsy is the most accurate test to confirm the diagnosis and to exclude other causes of muscle weakness or skin rash. However, choosing the right muscle for a biopsy is crucial to prevent a missing diagnosis. Further, the differential diagnosis includes body myositis, myasthenia gravis, muscular dystrophies, motor neuron disease, neuropathy, and inherited metabolic myopathy.

Further details related to diagnosis are provided in the report…

Dermatomyositis Epidemiology

For the purpose of designing the patient-based model for the Dermatomyositis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Diagnosed Prevalent Cases of Dermatomyositis, Type-specific Diagnosed Prevalent Cases of Dermatomyositis, Age-specific Diagnosed Prevalent Cases of Dermatomyositis, Gender-specific Diagnosed Prevalent Cases of Dermatomyositis, Severity-specific Diagnosed Prevalent Cases of Dermatomyositis, and Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.

The total diagnosed prevalent cases of Dermatomyositis in the United States were around 38.5 thousand cases in 2023.

The United States contributed to the largest diagnosed prevalent population of Dermatomyositis, acquiring ~54% of the 7MM in 2023. Whereas, EU4 and the UK, and Japan accounted for around 29% and 17% of the total population share, respectively, in 2023.

Among the EU4 countries, Germany accounted for the largest number of diagnosed prevalent Dermatomyositis (5,272 Cases) cases followed by the UK (4,594 Cases), whereas Spain accounted for the lowest number of cases (3,053 Cases) in 2023.

In 2023, it was estimated that there were around 15 thousand diagnosed cases in the age group of 40–59, followed by 13 thousand in 60–79 age group, 5,400 cases in 18–39 age group, 4,200 cases in 0–17 age group, and 1200 cases in 80 years and older in the US.

According to DelveInsight estimates, in 2023 there were approximately 6,937 diagnosed prevalent cases of Mild type and about 5,476 cases of Moderate to severe type in Japan.

In 2023, Dermatomyositis affected ~12 thousand males and ~26 thousand females in the United States.

In 2023, DelveInsight analysis of the chronicity-specific data in the US revealed that 70% of people affected with Dermatomyositis have Chronic type, while 30% have the Acute Type.

In Japan in 2023, comorbidity-specific cases accounted for the following percentages of diagnosed prevalent cases: ILD at 20%, CVD at 18%, cancer malignancy at 4%, and other conditions (including osteoporosis, dysphagia, Raynaud’s syndrome, calcinosis, etc.) at 58%.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the University of Chicago Medicine, US; Joe DiMaggio Children’s Hospital, FL, US; Department of Dermatology, Perelman Center for Advanced Medicine, the US; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Strasbourg University Hospital, Strasbourg, France; Sandwell and West Birmingham Hospitals NHS Trust, UK; Osaka University Graduate School of Medicine, Suita, Japan; Kanagawa Children’s Medical Center, JapanKyushu University, Fukuoka, Japan; and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

The report covers a segment of key events, an executive summary, descriptive overview of Dermatomyositis, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.

Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.

The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.

A detailed review of current challenges in establishing the diagnosis.

Dermatomyositis Report Insights

Patient Population

Country-wise Epidemiology Distribution

Total Diagnosed Prevalent Cases of Dermatomyositis

Age-specific Diagnosed Prevalent Cases of Dermatomyositis

Gender-specific Diagnosed Prevalent Cases of Dermatomyositis

Severity-specific Diagnosed Prevalent Cases of Dermatomyositis

Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis

Comorbidity-specific Diagnosed Prevalent Cases of Dermatomyositis

Dermatomyositis Report Key Strengths

11 years Forecast

The 7MM Coverage

Dermatomyositis Epidemiology Segmentation

Dermatomyositis Report Assessment

Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

What are the disease risk, burdens, and unmet needs of Dermatomyositis? What will be the growth opportunities across the 7MM concerning the patient population of Dermatomyositis?

What is the historical and forecasted Dermatomyositis patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?

Why is the diagnosed prevalent cases of Dermatomyositis in Japan lower than the US?

Which country has a high patient share for Dermatomyositis?

Reasons to Buy

Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand the Dermatomyositis prevalence cases in varying geographies over the coming years.

A detailed overview of Gender and Age Grade-specific diagnosed prevalence of Dermatomyositis, along with diagnosed prevalence of Dermatomyositis Based on severity of airflow limitation and diagnosed prevalence of Dermatomyositis based on symptoms and exacerbation history.

To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.

Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Dermatomyositis Epidemiology report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Dermatomyositis cases in 2023?

The highest cases of Dermatomyositis was found in the Germany among EU4 and the UK in 2023.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Dermatomyositis cases in 2023?

The highest cases of Dermatomyositis were found in the US among the 7MM in 2023.